2 recruiting, 1 not yet recruiting, 1 terminated. 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Recruiting 2, Not yet recruiting 1, Terminated 1 |
Follow Advanced Non Small Cell Lung Cancer (NSCLC): new trials by email Literature Review of Advanced Non Small Cell Lung Cancer (NSCLC) trials Research Report on Advanced Non Small Cell Lung Cancer (NSCLC)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase II Study of AK146D1 in Combination With AK112 in Advanced Non-Small Cell Lung Cancer AK146D1 for injection, AK112 Injection, Platinum chemotherapy - Advanced Non Small Cell Lung Cancer (NSCLC) | Phase 2 | Recruiting | Akeso | 348 | 2026-07-10 | 2026-07-14 |
| Clinical Effects of Alpha-Lipoic Acid in Advanced NSCLC Alpha Lipoic Acid 600mg - Advanced Non Small Cell Lung Cancer (NSCLC) | Phase 2 | Not yet recruiting | Ain Shams University | 60 | 2026-04-20 | 2026-05-08 |
| Optimal Methods to Characterize ADC Resistance in Solid Tumors and Identify Clinically Useful Biomarkers Biological samples collection, questionnaires to collect patient reported outcomes - Advanced Breast Cancer, Advanced Gastric Cancer | Phase 2 | Recruiting | UNICANCER | 400 | 2025-11-14 | 2025-12-02 |
| An Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR Mutations AUY922, Docetaxel, Pemetrexed - Advanced Non Small Cell Lung Cancer (NSCLC) | Phase 2 | Terminated | Novartis Pharmaceuticals | 59 | 2012-11-23 | 2019-07-24 |
Carcinoma, Non-Small-Cell Lung (2) · Adenocarcinoma of Lung (1) · Disease Progression (1) · Lung Neoplasms (1)
Bronchial Neoplasms (2) · Carcinoma, Bronchogenic (2) · Lung Diseases (2) · Neoplasms (2) · Neoplasms by Site (2) · Respiratory Tract Diseases (2) · Respiratory Tract Neoplasms (2) · Thoracic Neoplasms (2) · Adenocarcinoma (1) · Carcinoma (1) · Disease Attributes (1) · Lung Neoplasms (1) · Neoplasms by Histologic Type (1) · Neoplasms, Glandular and Epithelial (1) · Pathologic Processes (1)
5-(2,4-dihydroxy-5-isopropylphenyl)-4-(4-morpholin-4-ylmethylphenyl)isoxazole-3-carboxylic acid ethylamide (1) · Docetaxel (1) · Injections (1) · Pemetrexed (1) · Thioctic Acid (1) · osimertinib (1)
Ain Shams University (1) · Akeso (1) · Novartis Pharmaceuticals (1) · UNICANCER (1)
France (2) · China (1) · Hong Kong (1) · Italy (1) · Japan (1) · Netherlands (1) · Norway (1) · Poland (1) · South Korea (1) · Spain (1) · Taiwan (1) · United Kingdom (1) · United States (1)